FeesSafety
Pluang+

Chainlink partners with LG CNS to boost Korean won stablecoins and digital asset infrastructure.

Protocol Fundamentals
23 Oct 2026
Blockonomi
View Source
Bullish
Chainlink partners with LG CNS to boost Korean won stablecoins and digital asset infrastructure.

Chainlink has formed a strategic partnership with LG CNS, the IT and AI services arm of South Korea's LG Group, to expand the use and distribution of Korean won stablecoins. LG CNS will integrate Chainlink's cross-chain and data tools into its digital asset platform, targeting Korean financial institutions. This collaboration aims to support South Korea's $68 billion crypto market and advance the country's digital asset framework amid ongoing regulatory developments. No financial terms or launch timeline were disclosed.

Chainlink's partnership with LG CNS to expand Korean won stablecoins is the subject, with Pluang market data as context for readers. As of Oct 23, 2026 16:51 WIB, out of 50 major cryptocurrencies priced on Pluang, 31 rose and 18 fell. Notable movers include GRT at Rp437 with a 1-day change of +2.41% and a Pluang order activity of 4% Sell / 96% Buy, ENJ at Rp480 down 2.30% with 90% Sell / 10% Buy, and CAKE at Rp39,721 up 2.17% with 55% Sell / 45% Buy. The longest typical hold time on Pluang among these is ENJ at 105 days.

More News

Zinc and tin supply shortages revive interest in historic US mining districts with new drilling results.

Zinc and tin supply shortages revive interest in historic US mining districts with new drilling results.

Global zinc supply is expected to fall short by 88,000 tonnes in 2026 amid declining mine production, while tin demand is projected to outpace supply growth through 2035. This has renewed exploration in historic polymetallic mining districts in the U...

Market News
Bullish
17 minutes ago
Avacta's AVA6103 shows promise against Enhertu-resistant tumors in early trial and preclinical data

Avacta's AVA6103 shows promise against Enhertu-resistant tumors in early trial and preclinical data

Avacta Therapeutics presented positive preclinical and early clinical data for AVA6103, a novel peptide-drug conjugate targeting FAP-positive tumors resistant to Enhertu. AVA6103 demonstrated superior tumor control and prolonged drug release in precl...

Market News
Bullish
1 hour ago
Obra Capital closes $403.6M CLO deal, pushing total CLO issuance over $2B in under two years.

Obra Capital closes $403.6M CLO deal, pushing total CLO issuance over $2B in under two years.

Obra Capital has closed its fifth Collateralized Loan Obligation (CLO) offering, raising $403.6 million. This deal brings the firm's total CLO issuance to more than $2 billion across five deals in less than two years, demonstrating strong investor co...

Company Fundamentals
Bullish
1 hour ago
Padeliporfin VTP shows promise in making unresectable pancreatic cancer operable in Phase 1 trial

Padeliporfin VTP shows promise in making unresectable pancreatic cancer operable in Phase 1 trial

ImPact Biotech reported positive early results from its Phase 1 trial of Padeliporfin VTP in patients with locally advanced, unresectable pancreatic cancer. Of 12 patients treated, 75% have undergone or are scheduled for surgery, with over half achie...

Company Fundamentals
Bullish
1 hour ago
eSoftware offers a quick diagnostic to help organizations secure sensitive files before Microsoft 365 Copilot rollout.

eSoftware offers a quick diagnostic to help organizations secure sensitive files before Microsoft 365 Copilot rollout.

eSoftware Associates has introduced a free five-minute AI readiness assessment to help regulated organizations identify and prioritize security risks related to sensitive file access in Microsoft 365 before deploying Copilot. The assessment highlight...

Others
Neutral
2 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App